Mostrando 10 resultados de: 135
Filtros aplicados
Publisher
Pharmacogenomics(20)
Drug Metabolism and Personalized Therapy(11)
Drug Metabolism and Drug Interactions(9)
European Journal of Clinical Pharmacology(8)
Pharmacogenomics Journal(8)
Área temáticas
Farmacología y terapéutica(108)
Enfermedades(58)
Medicina y salud(39)
Fisiología humana(21)
Bioquímica(20)
Área de conocimiento
Genética(21)
Medicamento(10)
Psicopatología(10)
Química analítica(5)
Trastorno depresivo mayor(2)
4th ESPT Conference: Pharmacogenomics and personalized medicine - Research progress and clinical implementation
ArticleAbstract: The Fourth European Society of Pharmacogenomics and Personalized Therapy biennial conference was orgPalabras claves:clinical implementation, ESPT conference, personalized medicine, PharmacogenomicsAutores:Adrián LLerena, Ansari M., Cascorbi I., Drago F., Gozzo L., Ingelman-Sundberg M., Katsila T., Manolopoulos V.G., Marc J., Marchetti P., Meyer U.A., Mlakar V., Nofziger C., Paulmichl M., Pearson E., Re M.D., Simmaco M., Sipeky C., Stanković S., Suarez-Kurtz G., Van Schaik R.H.N.Fuentes:scopusA Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Bishop J.R., Bousman C.A., Caudle K.E., Gaedigk A., Gammal R.S., Hicks J.K., Klein T.E., Leeder J.S., Muller D.J., Ramsey L.B., Sangkuhl K., Scott S.A., Skaar T.C.Fuentes:scopusA Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
ArticleAbstract: Background: The characterization of the first episode of psychosis and how it should be treated arePalabras claves:Antipsychotic, first episode psychosis, pharmacovigilance, polytherapy, psychotropic drugs, SchizophreniaAutores:Adrián LLerena, Aguilar E.J., Albacete A., Alonso-Solís A., Amoretti S., Baeza I., Balanzá-Martínez V., Bernardo M., Bioque M., Bobes J., Bulbena A., Butjosa A., Cabrera B., Castro-Fornieles J., Contreras F., Corripio I., Cuesta M.J., Díaz-Caneja M.C., Escartí M.J., García Bernardo E., García-Portilla M.P., Gassó P., González I., González-Pinto A., Grasa E., Hernandez M., Ibáñez Á., Lafuente A., Landín-Romero R., Lobo A., Mané A., Mas S., Mezquida G., Modrego F., Morales-Muñoz I., Parellada M., Rodriguez-Jimenez R., Ruiz P., Saiz-Ruiz J., Sánchez-Torres A.M., Sarró S., Segarra R., Tapia-Casellas C., Torrent C., Vieta E., Zabala Rabadán A.Fuentes:scopusA rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity
ArticleAbstract: Background: The analytical method here reported for the CEIBA cocktail approach has been developed aPalabras claves:Autores:Adrián LLerena, de Andrés F., Sosa-Macías M.G.Fuentes:scopusChallenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
ArticleAbstract: Purpose: The symposium Health and Medicines in Indigenous Populations of America was organized by thPalabras claves:CIOMS-RIBEF, clinical research, pharmacogenetics, resource-limited settingsAutores:Adrián LLerena, Diwakar S., Enrique Terán, Galaviz-Hernandez C., Gil J.P., Isabel Hernández, Lara-Riegos J., Molina-Guarneros J.A., Moya G.E., Nair S., Penãs-Lledó E.M., Rägo L., Ramírez-Roa R., Sosa-Macías M.G., Tarazona-Santos E.M., Verde I.Fuentes:googlescopusCharacterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update
ReviewAbstract: Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokiPalabras claves:Autores:Adrián LLerena, Callaghan J.T., Caudle K.E., Fohner A.E., Formea C.M., Gaedigk A., Huddart R., Karnes J.H., Klein T.E., Mintzer S., Phillips E.J., Rettie A.E., Somogyi A.A., Ta Michael Lee M., Whirl-Carrillo M.Fuentes:scopusClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors
ArticleAbstract: Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive aPalabras claves:Autores:Adrián LLerena, Bishop J.R., Caudle K.E., Chiulli D.L., Gaedigk A., Graham R.L., Hicks J.K., Ji Y., Klein T.E., Leckband S.G., Leeder J.S., Muller D.J., Sangkuhl K., Scott S.A., Skaar T.C., Stingl J.C.Fuentes:scopusClinical drug-drug interactions: Focus on venlafaxine
ReviewAbstract: Venlafaxine (VEN) is an antidepressant agent widely used nowadays as an alternative to selective serPalabras claves:Drug-drug interactions, pharmacodynamics, pharmacokinetics, VenlafaxineAutores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusClinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopus